期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他汀类药物预防缺血性卒中的作用研究进展 被引量：32

在线阅读 下载PDF
导出
摘要 脑卒中具有高复发率和高死亡率的特点．其中缺血性卒中具有更高的发病率，如何有效地预防缺血性卒中的发生具有积极的意义。近年来的研究强化了血脂与缺血性卒中的关系,其中研究的焦点为低密度脂蛋白（LDL）水平与缺血性卒中之间的关系，目前无论从一级预防或者二级预防都证实LDL与缺血性卒中相关，他汀类药物作为有效降低低密度脂蛋白胆固醇（LDL—C）水平的药物，必然在脑血管病中发挥重要作用。
作者 郭亚东 徐安定
机构地区 暨南大学附属第一医院神经内科
出处 《实用医学杂志》 CAS 2008年第1期1-3,共3页 The Journal of Practical Medicine
关键词 缺血性卒中 他汀类药物 药物预防 低密度脂蛋白胆固醇 高死亡率 高复发率 二级预防 一级预防
分类号 R743 [医药卫生—神经病学与精神病学] R54 [医药卫生—心血管疾病]
  • 相关文献

参考文献20

  • 1Cholesterol,diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts:prospective studies collaboration [J]. Lancet, 1995,346(8991-8992) : 1647-1653.
  • 2Song Y M, Sung J, Lawlor D A, et al. Blood pressure, haemorrhagic stroke, and ischaemic stroke:the Korean national prospective occupational cohort study [J]. BMJ, 2004,328 (12) : 324-325.
  • 3Iso H, Jacohs D R,Jr, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial [J]. N Engl J Med, 1989, 320(14) : 904-910.
  • 4Amarenco P, Labreuche J, Lavallee P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-todate meta-analysis [J]. Stroke, 2004,35(12) :2902-2909.
  • 5Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease [J], Lancet, 1994,344(8934) : 1383-1389.
  • 6Plehn J F, Davis B R, Sacks F M, et al. Reduction of stroke incidence after myocardial infarction with pravastatin : the cholesterol and recurrent events (CARE) study [J]. Circulation, 1999,99(2) :216-223.
  • 7The Long-Term Investigation with Pravastion in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels [J]. N Engl J Med, 1998, 339(19) : 1349-1357.
  • 8Heart Protection Study Collaborative Group. Effects of cholesterotlowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions [ J ]. Lancet, 2004,363 ( 9411 ) : 757-767.
  • 9The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators:high-dose atorvastatin after stroke or transient ischemic attack [J], N Engl J Med, 2006,355 (6): 549-559.
  • 10Llorente-Cortes V, Martynez-Gonzalez J, Badimon L. Esterified cholesterol accumulation induced by aggregated LDL up take in human vascularsmooth muscle cells is reduced by HMG-CoA reductase in hibitors [J]. Arterioscler Thromb Vasc Biol, 1998, 18 (5) :738-746.

二级参考文献14

  • 1Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP)Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults ( Adult Treatment Panel Ⅲ). JAMA,2001,285 : 2486-2497.
  • 2Baigent C, Keech A, Keamey PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet,2005,366 : 1267-1278.
  • 3Sacco RL, Adams R, Albers G,et al. Guidelines for prevention of stroke in patients with ischemic stroke or transiem ischemic attack: a statemem for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology Affirms the value of this guideline. Circulation ,2006,113 : e409-e449.
  • 4Cannon CP,Steinberg BA, Murphy SA,et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coil Cardiol, 2006,48:438-445.
  • 5Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 2006,355:549-559.
  • 6Guyton JR. Benefit versus risk in statin treatment. Am J CardioI, 2006,97 (SA) :95C-97C.
  • 7Gotto AM Jr. Statins, cardiovascular disease, and drug safety. Am J Cardiol,2006,97(8A) :3C-5C.
  • 8Thompson PD, Clarkson PM, Rosenson RS, et al. An assessment of statin safety by muscle experts. Am J Cardiol,2006,97(8A) : 69C-76C.
  • 9Cohen DE, Anania FA, Chalasani N, et al. An assessment of statin safety by hepatologists. Am J Cardiol, 2006,97(8A) :T/C-81C.
  • 10LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Meal,2005,352:1425-1435.

共引文献123

同被引文献210

引证文献32

二级引证文献254

实用医学杂志
2008年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部